MannKind is a biotechnology business based in the US. MannKind shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.00 – an increase of 5.71% over the previous week. MannKind employs 403 staff and has a trailing 12-month revenue of around $285.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.00 |
|---|---|
| 52-week range | $4.17 - $7.63 |
| 50-day moving average | $5.00 |
| 200-day moving average | $5.91 |
| Wall St. target price | $10.29 |
| PE ratio | 50 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5 from 2025-05-02
| 1 week (2025-04-28) | 5.71% |
|---|---|
| 1 month (2025-04-04) | 5.49% |
| 3 months (2025-02-05) | -11.35% |
| 6 months (2024-11-05) | -31.13% |
| 1 year (2024-05-03) | 13.90% |
|---|---|
| 2 years (2023-05-05) | 26.26% |
| 3 years (2022-05-05) | 62.87% |
| 5 years (2020-05-05) | 273.13% |
Valuing MannKind stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MannKind's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MannKind's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, MannKind shares trade at around 50x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
MannKind's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $76.1 million.
The EBITDA is a measure of a MannKind's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $285.5 million |
|---|---|
| Operating margin TTM | 28.74% |
| Gross profit TTM | $208.9 million |
| Return on assets TTM | 9.88% |
| Return on equity TTM | 0% |
| Profit margin | 9.66% |
| Book value | $-0.26 |
| Market Capitalization | $1.5 billion |
TTM: trailing 12 months
We're not expecting MannKind to pay a dividend over the next 12 months.
MannKind's shares were split on a 1:5 basis on 2 March 2017 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind shares which in turn could have impacted MannKind's share price.
Over the last 12 months, MannKind's shares have ranged in value from as little as $4.165 up to $7.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind's is 1.213. This would suggest that MannKind's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S. A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.